1ISG-014 RHEUMATOID ARTHRITIS: BIOLOGICAL DRUGS PHARMACEUTILISATION ANALYSIS IN AN ITALIAN DISTRICT

E Viglione*, M Lecis, S Strobino, G Ceravolo. ASL TO3, Hospital Pharmacy, Rivoli, Italy

10.1136/ejhp-pharm-2019-eahpconf.14

Background Rheumatoid arthritis is a chronic systemic inflammatory disease that concerns, above all, the industrialised countries and it has a high rate of development. According to the World Health Organization, the rheumatoid arthritis prevalence in the world is between 0.3% and 1% and in Italy is equivalent to 0.33/100, that is about 2 00 000 patients.

Purpose The aim of this work consists in comparing prescriptions between an Italian district, including 6 00 000 citizens, and regional and national prescriptions, in order to make a pharmaceutisation analysis.

Material and methods Immunosuppressive drugs have been analysed (Anatomical Therapeutic Chemical (ATC) classification: L04), employed in rheumatoid arthritis therapy, according to the defined daily dose (DDD), divided in the ATC classification, concerning the two-year period 2016/2017. Prescriptions concerning an Italian district, the region of belonging and the whole nation have been compared.

Results In an Italian north district, DDDs concerning immunosuppressive prescriptions for rheumatoid arthritis have been increased by 14.6% in 2017 compared with the previous year, however they are being on regional and national average. DDDs that have increased more concern secukinumab (+1135.3%) and, in less quantity, tocilizumab (+59.6%). In 2017, every molecules considered DDDs are increased except etanercept and infliximab in the region, and mycophenolate in general in the nation, compared to 2016. Immunosuppressive drugs belonging to ATC L04 totals 2.2% of the whole DDD. In 2017, DDDs increased in this district (+14.6%) and also in the region and national territory.

Conclusion From this analysis, it can be said that in 2017 there has been a DDD increase in molecules belonging to ATC L04 prescribed for rheumatoid arthritis. The pharmaceutical market is booming thanks to the frequent introduction of new molecules and the updating of new therapeutic indications. It is necessary for continuous training of prescribers and pharmacists to ensure prescriptive appropriateness in order to deliver suitable and effective therapy to patients, and economic sustainability.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Biosimilar position paper AIFA.

No conflict of interest.

1ISG-015 OPTIMISATION OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS

A Dominguez*, A Fernandez-Corada, A Garcia, S Gonzalez, R Lopez, C Blazquez, N Labrador, P Moya. Hospital Virgen de la Salud, Pharmacy, Toledo, Spain

10.1136/ejhp-pharm-2019-eahpconf.15

Background The use of biological treatments for psoriasis involves a significant improvement in disease management. However, the economic impact of its use on health systems is high.

Optimised treatment patterns of biological therapies, in clinically controlled patients, attempt to find a more efficient use of these drugs.

Purpose To analyse patients with psoriasis on an optimised pattern of biological treatment and to estimate the annual saving of these optimised patterns in a third-level hospital.

Material and methods Observational, retrospective and longitudinal study of psoriasis patients treated with biologic drugs in a general hospital of 650 beds. Medical records review and a retrospective analysis of prescriptions registered in the integral external Patient Information System and in the computerised History System was carried out up to 30 September 2018.

We recorded demographic data (age, sex), type of biological therapy, clinical control of disease, optimised therapy yes/no and the annual economic impact due to every drug in an optimised pattern.

Results One hundred and fifty patients diagnosed with psoriasis were included, 102 (68%) men and 48 (32%) women, aged between 9 and 87 years (median 46.8 years).

Patient distribution according to the biologic drug used, number of patients in optimised treatment patterns and the estimated saving per patient per year are included in table 1.

Abstract 1ISG-015 Table 1

Biological Drug	Total Patients	Optimised Therapy Patients	Estimated Saving Per Patient Per Year (€)	Estimated Saving Per Year (€)
Etanercept	7	3 (42.86%)	3700*	11 200
Adalimumab	33	11 (33.35%)	4600*	50 900
Ustekinumab	73	23 (31.5%)	7200*	62 000
Secukinumab	15	6 (40%)	4000*	23 900
Ixekizumab	7	1 (14.9%)	2300	2300
Apremilast	15	4 (26.67%)	4200*	16 900
Total	150	48 (32%)*		167.200

*median

Forty-eight patients (32%) were in treatment with an optimised biological therapy pattern.

It is estimated that with these optimised biological therapies the annual saving is around € 1 60 000.

Conclusion The number of our patients receiving individualised biological treatment for psoriasis is more than one-third, which allows the same clinical effects with less economic impact on our health system.

The estimated savings per year in our hospital due to optimised biological treatments for psoriasis is important because quality of treatment is not affected.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

1ISG-016 COST-EFFECTIVENESS OF MORPHINE VERSUS FENTANYL IN MANAGING VENTILATED NEONATES WITH RESPIRATORY DISTRESS SYNDROME IN THE INTENSIVE CARE SETTING

¹D Abushanab*, ¹O Alsoukni, ²F Abonahia, ³D Al-Badriyeh. ¹Hamad Medical Corporation, Pharmacy, Doha, Qatar; ²Hamad Medical Corporation, Neonatal Intensive Care Unit, Doha, Qatar; ³Qatar University, College of Pharmacy, Doha, Qatar

10.1136/ejhp-pharm-2019-eahpconf.16

Background The use of opioids as sedatives is necessary for agitated neonates undergoing mechanical ventilation (MV) with respiratory distress syndrome (RDS) in a neonatal

intensive care unit (NICU), to facilitate the procedure of MV and enhance the ventilator-patient synchrony, in addition to pain relief.

Purpose To perform a cost-effectiveness analysis of morphine versus fentanyl in agitated neonates with RDS undergoing MV in the NICU setting.

Material and methods A retrospective cost-effectiveness analysis of critically ill neonates with RDS receiving morphine versus fentanyl at a Women's Wellness and Research Centre. The clinical data of neonates were extracted from the medical records of patients within the 2014–2016 period. A decision analytic model, from the hospital perspective, was constructed to follow the possible consequences of sedation. The primary endpoints were the successful drug sedation rate, based on the Premature Infant Pain Profile (PIPP) scoring scale, and the overall direct medical cost of therapy of managing acute agitation in the neonates. A study population size of 124 neonates was calculated to achieve results with 80% power and P0.05 significance. Sensitivity analyses were conducted to enhance the robustness of conclusions against input uncertainties, and increase the generalisability of results.

Results All baseline demographic characteristics were not significantly different between both groups. A multivariate analysis of covariance model demonstrated that the statistical difference between morphine and fentanyl did not statistically change after accounting for baseline differences of values of PIPP scores, birthweight and gestational age (P-value=1.00). Morphine achieved a sedation success of 68%, versus 43% with fentanyl, risk ratio 1.72, 95% CI 1.16 to 2.56, P-value=0.0075. Morphine was associated with a minimal incremental cost-effectiveness ratio of \$135 per additional case of sedation over fentanyl. Based on uncertainty analyses, however, this higher morphine cost was reported in only 2% of patient cases. Sensitivity analyses demonstrated insensitivity of the study model to the study input uncertainties, except for the NICU stay and cost of MV.

Conclusion This is the first cost-effectiveness evaluation of morphine versus fentanyl in a NICU. Morphine significantly improved sedation over fentanyl. There is a 98% probability that morphine is dominant over fentanyl.

REFERENCES AND/OR ACKNOWLEDGEMENTS

We acknowledge the receipt of study funding by the Office of Academic Research.

No conflict of interest.

1ISG-017

CLINICAL AND ECONOMIC EVALUATIONS OF MORPHINE AND FENTANYL WITH MECHANICAL VENTILATION IN INTENSIVE CARE SETTINGS: A SYSTEMATIC REVIEW OF METHODOLOGICAL TRENDS AND REPORTING QUALITY

¹D Abushanab*, ¹O Alsoukhni, ²D Al-Badriyeh. ¹Hamad Medical Corporation, Pharmacy, Doha, Qatar; ²Qatar University, College of Pharmacy, Doha, Qatar

10.1136/ejhp-harm-2019-eahpconf.17

Background Patients with respiratory disorders, including respiratory distress syndrome (RDS), require mechanical ventilation (MV) to maintain the pulmonary function. MV, however, is an invasive procedure that requires the administration of sedatives to simplify the procedure. Fentanyl and morphine are widely used opioids as sedatives in the intensive care unit (ICU).

While there is less potential of morphine to cause tolerance, fentanyl has a faster onset and shorter duration of action.

Purpose To summarise the characteristics and gaps in methods and quality of reports of the comparative clinical and economic evaluations on the use of fentanyl and morphine in patients with respiratory disorders undergoing MV in the ICU settings.

Material and methods The electronic databases Medline, Embase, OVID, Science Direct, Springer Link and EconLit were used to identify comparative studies of either fentanyl or morphine or both, in the management of ventilated patients with respiratory disorders in the ICU. The outcome measures were the trends of methodological characteristics and designs of included studies. Appraisal of studies was performed via the Consolidated Standards of Reporting Trials, Strengthening the Reporting of Observational Studies in Epidemiology and Consolidated Health Economic Evaluation Reporting Standards checklists.

Results Among 1327 found articles, 33 met the inclusion criteria. Twenty-two studies were conducted in adults, eight in neonates and three in paediatrics. No head-to-head morphine versus fentanyl evaluation was explicitly undertaken only in participants with respiratory conditions. Studies relied on various types of scales to measure the sedation level as a primary study outcome, which limits the comparability of conclusions. Economic outcomes were evaluated in seven studies, only in adults and all from the hospital perspective. The same sedation regimen performed differently in various studies based on different endpoints. All of the randomised controlled trials, observational cohort and pharmacoeconomics studies did not meet the majority of assessed reporting quality criteria.

Conclusion Although the use of sedative regimens to manage mechanically ventilated patients with respiratory disorders is very high, the heterogeneity of studies disables the comparison of findings and, consequently, the construction of clear conclusions regarding the most effective and cost-effective sedatives. Evidence generated from poor reported studies may result in uninformed decisions by decision makers.

REFERENCES AND/OR ACKNOWLEDGEMENTS

None.

No conflict of interest.

1ISG-018

ORGANISATIONAL COMMITMENT OF HOSPITAL PHARMACISTS, RELATING TO THE SUPPORTIVE ORGANISATIONAL ENVIRONMENT

M Ahn*, H Jeong. Veterans Health Service Medical Centre, Pharmacy Department, Seoul, South Korea

10.1136/ejhp-harm-2019-eahpconf.18

Background As hospital pharmacists have expanded their role from simple drug dispensing to patient-oriented clinical practice, they have augmented their professionalism (the attitudes and belief as professional (PF)) as hospital pharmacists. Thus it has been important to make them commit to hospital organisation.

Purpose This study examines how a supportive organisational environment (SOE) influences organisational commitment (the attitudes and behaviours to devote themselves to their organisation (OC)) of hospital pharmacists in South Korea. In particular, we have analysed the role of professionalism in the relationship.